Showing 501-510 of 21412 results for "".
- Diabetes Prevention and Education: Lifestyle Interventions in Focushttps://reachmd.com/news/diabetes-prevention-and-education-lifestyle-interventions-in-focus/2474367/With rising rates of diabetes, prediabetes, and obesity, healthcare professionals are leveraging educational programs that combine nutritional guidance with structured physical activity to halt disease progression and empower patients. Overview
- Emerging Biomarkers in Diabetic Retinopathy: The Potential Role of Pentraxin 3 and Stress Hyperglycemia Ratiohttps://reachmd.com/news/emerging-biomarkers-in-diabetic-retinopathy-the-potential-role-of-pentraxin-3-and-stress-hyperglycemia-ratio/2475732/Subclinical microvascular injury in patients with diabetes often goes unnoticed until vision is compromised, underscoring an urgent need for diagnostic tools that detect early retinal changes and preserve quality of life through timely i
- Could a Common Diabetes Drug Ease Knee Osteoarthritis Pain—and Delay Surgery?https://reachmd.com/news/drug-repurposing-diabetes-medication-for-managing-knee-osteoarthritis-pain/2474341/In an era where repurposing familiar drugs has become a promising frontier in medicine, metformin—a stalwart in type 2 diabetes care—is stepping into an unexpected new role. Recent clinical trials suggest that this decades-old medication may significantly reduce kn
- Early and Sustained Depemokimab Efficacy in Type 2 Asthmahttps://reachmd.com/news/depemokimab-efficacy-type-2-asthma/2487396/Key Takeaways Depemokimab was associated with a 46% lower probability of first exacerbation over 52 weeks, with benefit reported from week 4 and sustained across both dosing periods. Improvements were also reported in St George's Respiratory Questionna
- Early and Sustained Depemokimab Efficacy in Type 2 Asthmahttps://reachmd.com/news/early-and-sustained-depemokimab-efficacy-in-type-2-asthma/2486867/Key Takeaways Depemokimab was associated with fewer first exacerbations than placebo over 52 weeks, and benefit appeared by week 4. Improvements were reported across each 26-week dosing period in symptom and quality-of-life measures, with sustained res
- GLP-1 Receptor Agonists Linked to Lower Risk of Early-Onset Colorectal Cancer in Diabetic Patientshttps://reachmd.com/news/glp-1-receptor-agonists-linked-to-lower-risk-of-early-onset-colorectal-cancer-in-diabetic-patients/2468569/In a promising development for cancer prevention, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), commonly used in diabetes management, have been linked to a reduced risk of early-onset colorectal cancer (EO-CRC) in patients under 50 with type 2 diabetes. These findings, presented at the r
- Cleveland Clinic Study Shows Bariatric Surgery Outperforms GLP-1 Diabetes Drugs for Kidney Protectionhttps://reachmd.com/news/cleveland-clinic-study-shows-bariatric-surgery-outperforms-glp-1-diabetes-drugs-for-kidney-protection/2468276/A Cleveland Clinic study showed that in patients with type 2 diabetes, obesity, and chronic kidney disease, bariatric surgery was associated with a significant decrease in the progression of chronic kidney disease compared to those who received GLP-1 diabetes medications. The paper was
- The Role of Gut-Derived Metabolites in Diabetes and Liver Healthhttps://reachmd.com/news/the-role-of-gut-derived-metabolites-in-diabetes-and-liver-health/2475934/Understanding how gut-derived metabolites impact blood sugar regulation and liver health is at the forefront of innovative diabetes management. As diabetes prevalence climbs, clinicians face mounting complexity in tailoring metabolic control. Emerging research highlights that microbi
- Early Detection of Overlapping Neuropathies in Diabeteshttps://reachmd.com/news/early-detection-of-overlapping-neuropathies-in-diabetes/2475984/Up to one in three patients with long-standing diabetes exhibits overlapping sensory and autonomic neuropathies months before clinical suspicion arises, reshaping how endocrinologists and neurologists must approach early detection, according to the American Diabetes Association’s
- Advancing Diabetes Risk Prediction through the CRP-Triglyceride Glucose Indexhttps://reachmd.com/news/biomarker-innovation-advancing-diabetes-risk-prediction-through-the-crp-triglyceride-glucose-index/2485036/Cumulative exposure to the c-reactive protein-triglyceride glucose index (CTI) predicts higher incident diabetes risk in middle-aged and older adults, suggesting a readily ob